about
Constitutive activation of the Wnt canonical pathway in mantle cell lymphomaTruncation in CCND1 mRNA alters miR-16-1 regulation in mantle cell lymphomaCrystal structure of human CDK4 in complex with a D-type cyclinMYC-driven aggressive B-cell lymphomas: biology, entity, differential diagnosis and clinical managementFragment-Based Discovery of 7-Azabenzimidazoles as Potent, Highly Selective, and Orally Active CDK4/6 InhibitorsBlockade of fatty acid synthase triggers significant apoptosis in mantle cell lymphomaThe novel deacetylase inhibitor AR-42 demonstrates pre-clinical activity in B-cell malignancies in vitro and in vivoIntegrative gene expression profiling reveals G6PD-mediated resistance to RNA-directed nucleoside analogues in B-cell neoplasmsHigh expression of Mcl-1 in ALK positive and negative anaplastic large cell lymphoma.Targeting mantle cell lymphoma metabolism and survival through simultaneous blockade of mTOR and nuclear transporter exportin-1Degrasyn potentiates the antitumor effects of bortezomib in mantle cell lymphoma cells in vitro and in vivo: therapeutic implications.Knock-down of SOX11 induces autotaxin-dependent increase in proliferation in vitro and more aggressive tumors in vivo.Responses in mantle cell lymphoma cells to SNS-032 depend on the biological context of each cell line.Herpes simplex virus 1 mutant in which the ICP0 HUL-1 E3 ubiquitin ligase site is disrupted stabilizes cdc34 but degrades D-type cyclins and exhibits diminished neurotoxicityFTY720 shows promising in vitro and in vivo preclinical activity by downmodulating Cyclin D1 and phospho-Akt in mantle cell lymphoma.Metadherin contributes to the pathogenesis of diffuse large B-cell lymphomaExpression and effects of inhibition of type I insulin-like growth factor receptor tyrosine kinase in mantle cell lymphoma.Expression of histone deacetylases in lymphoma: implication for the development of selective inhibitors.Ribosomal Biogenesis and Translational Flux Inhibition by the Selective Inhibitor of Nuclear Export (SINE) XPO1 Antagonist KPT-185.Cyclin D1 as a therapeutic target of renal cell carcinoma- a combined transcriptomics, tissue microarray and molecular docking study from the Kingdom of Saudi Arabia.Molecular evidence of Zn chelation of the procaspase activating compound B-PAC-1 in B cell lymphoma.Dual targeting of the cyclin/Rb/E2F and mitochondrial pathways in mantle cell lymphoma with the translation inhibitor silvestrol.Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma.Protein arginine methyltransferase 5 (PRMT5) inhibition induces lymphoma cell death through reactivation of the retinoblastoma tumor suppressor pathway and polycomb repressor complex 2 (PRC2) silencing.Preclinical activity of 8-chloroadenosine with mantle cell lymphoma: roles of energy depletion and inhibition of DNA and RNA synthesis.Mantle cell lymphoma in cyclin D1 transgenic mice with Bim-deficient B cells.A key role for EZH2 in epigenetic silencing of HOX genes in mantle cell lymphoma.Combination of Pim kinase inhibitor SGI-1776 and bendamustine in B-cell lymphoma.B cell receptor signaling regulates metabolism in Chronic Lymphocytic Leukemia.Histone deacetylase inhibitors enhance CD1d-dependent NKT cell responses to lymphomaPreclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors.Involvement of tumor-associated macrophage activation in vitro during development of a novel mantle cell lymphoma cell line, PF-1, derived from a typical patient with relapsed disease.Transcription and translation are primary targets of Pim kinase inhibitor SGI-1776 in mantle cell lymphoma.Essential role of TAK1 in regulating mantle cell lymphoma survival.PRDM1 is required for mantle cell lymphoma response to bortezomib.All trans retinoic acid nanodisks enhance retinoic acid receptor mediated apoptosis and cell cycle arrest in mantle cell lymphoma.Cyclin D1 as a universally expressed mantle cell lymphoma-associated tumor antigen for immunotherapy.Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma.Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activity.The use of cellular thermal shift assay (CETSA) to study Crizotinib resistance in ALK-expressing human cancers.
P2860
Q24312127-864A2CF5-B6C9-4F4F-8F8A-0D82166A2A94Q24655119-F8D97D7C-69E2-4BF5-B3FE-C85EB47726D7Q24656160-EAB3DB55-5579-4110-851D-8BE23335F773Q26785379-E28DB0C8-66B7-4772-BFE3-25750A0A4EE7Q27684150-85139228-C32A-4FCC-8774-C0D1715A571BQ28730808-A86F3E35-5A58-44E6-998C-07DBAA6517C4Q28751751-BA66222A-2EA7-4F82-848B-0794A95A64EEQ31077729-D08368CD-D17C-44C1-AB8D-F72CCC37D856Q31164878-C3954016-CBD5-46F5-849F-0FBCEADF0F7CQ33798463-2CC18127-B92C-4433-B65D-72C1543D7BADQ33832937-14AEC385-D0A6-4F4F-B16F-AF3890702DD4Q34006685-EA7F2D96-8046-468F-9534-1F4EECC7A8C2Q34091061-3292A7B7-164F-4C53-BDAE-08AB9EDDE01BQ34227708-6403C85F-40FC-4665-AB3F-DAB8E7139977Q34269804-D9115EA2-205B-4DF1-A0DF-836ED5467B2BQ34328140-A49EDA0C-5C60-454D-9527-817E3FF58E42Q35018535-0CB4AEDA-C475-4624-814F-E0B9778E918DQ35235267-D16C9CA1-2AC0-4B44-B7D2-0661807F3B22Q35764599-DC37EF4C-22AC-4FD7-9635-78E304A1B639Q36170317-78873F8B-B794-4DE5-9B4C-119A23EEF2DFQ36772172-6C182B42-D1DB-40A1-AAB5-DEDD27290C3EQ36914970-35B95E3F-F24A-49C2-9A77-110A97CF9662Q37273485-E72074B9-22EC-407E-BD61-D991D301E888Q37368735-40E61B2A-9A3C-45CC-A122-4B2C52B29999Q37424558-3B6E29AF-8498-45EC-9C5F-A532A512DC40Q37564773-4EF9F44B-EC9C-4AFC-B3BA-74D38F345392Q37600907-790F9562-F1F7-49D3-8EB5-89FCDBE3CC60Q38260135-EA320B4F-9719-4D84-88A7-C1C0DB2263C7Q38611244-32B4D0D3-37BA-4823-B95A-A471CCEFB54CQ38740003-48235A3B-BD48-4950-BDA2-FBE67CCF06B8Q38832541-790741DB-2EE0-4983-9D2C-B31470893712Q39017105-98567D0B-F68C-4CB0-9B56-6BFD2B554056Q39283981-AD6C27CF-DF6A-46F4-86A1-3CB6A15528A9Q39339382-2AACA0FF-AC8B-4567-A9BB-8DA915CCEDA3Q39695887-2DF6CE1A-454C-44E6-AEC3-DF2DE25AE644Q39699466-CE0FE3E2-214E-469C-BD10-391777994B83Q39882401-0360906B-5778-4C22-A920-C603C82FEF8DQ40200306-BC050176-EE65-4B03-B1CE-3B85BB4D15B1Q40280853-49BFD744-D59E-47E6-82A1-35DF1CC0A972Q41116766-D4C81BF4-EAEB-4798-978C-C05F502C349E
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Characterization of 4 mantle cell lymphoma cell lines
@ast
Characterization of 4 mantle cell lymphoma cell lines
@en
Characterization of 4 mantle cell lymphoma cell lines
@nl
type
label
Characterization of 4 mantle cell lymphoma cell lines
@ast
Characterization of 4 mantle cell lymphoma cell lines
@en
Characterization of 4 mantle cell lymphoma cell lines
@nl
prefLabel
Characterization of 4 mantle cell lymphoma cell lines
@ast
Characterization of 4 mantle cell lymphoma cell lines
@en
Characterization of 4 mantle cell lymphoma cell lines
@nl
P2093
P4510
P3181
P1476
Characterization of 4 mantle cell lymphoma cell lines
@en
P2093
Georgios Z Rassidakis
Hesham M Amin
L Jeffrey Medeiros
Raymond Lai
Sean L O'Connor
Timothy J McDonnell
Vasiliki Leventaki
P304
P3181
P356
10.1043/0003-9985(2003)127<0424:COMCLC>2.0.CO;2
P407
P577
2003-04-01T00:00:00Z